KLRA Overview

Kailera Therapeutics, Inc. is a clinical-stage biotechnology company focused on obesity care. The Company is advancing four clinical-stage product candidates leveraging multiple GLP-1-based mechanisms of action and routes of administration specifically designed to address critical needs in the current therapeutic landscape with a lead product candidate, ribupatide injection (also known as KAI-9531), that has the potential for weight loss. Ribupatide injection is in global Phase III trials as a once-weekly injectable GLP-1/GIP receptor dual agonist. The Company is developing a once-daily oral tablet formulation, ribupatide oral, to provide a convenient oral option with compelling weight loss among oral treatments. Additionally, it is advancing the development of KAI-7535, a once-daily oral small molecule GLP-1 receptor agonist, and KAI-4729, a once-weekly injectable GLP-1/GIP/glucagon receptor tri-agonist.

Wall Street analysts forecast KLRA stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for KLRA is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Kailera Therapeutics Inc revenue for the last quarter amounts to -84.66M USD, decreased

Kailera Therapeutics Inc. EPS for the last quarter amounts to -68310000.00 USD, decreased

Kailera Therapeutics Inc (KLRA) has 145 emplpoyees as of June 20 2026.

Today KLRA has the market capitalization of 2.58B USD.